A Pilot Study of Metformin Treatment in Patients With Well-differentiated Neuroendocrine Tumors

NCT02279758 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Well-differentiated Neuroendocrine Tumors

Interventions

DRUG: Metformin

Sponsor

Instituto do Cancer do Estado de São Paulo